Feasibility of altering type A behavior pattern after myocardial infarction. Recurrent Coronary Prevention Project Study: methods, baseline results and preliminary findings.
Circulation., Jul;66(1):83-92 (1982)
Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial.
JAMA., Apr;271(13):999-1003 (1994)
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
JAMA., Apr;283(14):1845-52 (2000)
A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
Circulation., Apr;87(4 Suppl):III45-53 (1993)
AHA Conference Report on Cholesterol. Intervention studies.
Circulation., Sep;80(3):739-43 (1989)
Currently available lipid-lowering agents.
Hosp. Pract. (Off. Ed.)., Jun;23 Suppl 1:14-21 (1988)
Progression of coronary atherosclerosis in patients with probable familial hypercholesterolemia. Quantitative arteriographic assessment of patients in NHLBI type II study.
Arteriosclerosis., 9(1 Suppl):I81-90 (1989)
Current therapy for hypercholesterolemia.
JAMA., 261(24):3582-7 (1989)
Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men.
Lancet., Jul;2(8550):62-6 (1987)
Report on the Lipid Research Clinic trials.
Eur. Heart J., Aug;8 Suppl E:45-53 (1987)
Changing perspectives in the prevention of coronary artery disease.
Am. J. Cardiol., May;57(14):17G-26G (1986)
Role of dietary intervention in the primary prevention of coronary heart disease. Individuals with high-normal or elevated serum cholesterol levels should be placed on cholesterol-lowering diets.
Cardiology., 74(1):2-21 (1987)
Planning and implementation of large clinical trials.
Isr. J. Med. Sci., 22(3-4):191-6 (1986)
Cholesterol and coronary artery disease. What do clinicians do now?
Am. J. Med., Feb;80(2A):18-22 (1986)
Some clinical implications of the results of the Lipid Research Clinics Program Prevalence Study.
Circulation., Jan;73(1 Pt 2):I126-33 (1986)
Secondary prevention and lipid lowering: results and implications.
Am. Heart J., Nov;110(5):1123-7 (1985)
Primary prevention of coronary heart disease by lowering lipids: results and implications.
Am. Heart J., Nov;110(5):1116-22 (1985)
Causes of the decrease in cardiovascular mortality.
Am. J. Cardiol., Aug;54(5):7C-13C (1984)
Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.
Circulation., Feb;69(2):313-24 (1984)
The dilemma of 'mild' hypertension. Another viewpoint of treatment.
JAMA., Dec;250(23):3171-3 (1983)